The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.

HOUSTON – (Sept. 13, 2021) – Progress on treating Alzheimer’s disease has been frustratingly slow. A group of scientists in Houston suggest frustration at a very small scale may lead to a new path ...

There is great interest in developing selective protein kinase inhibitors by targeting allosteric sites, but these sites often involve protein-protein or protein-peptide interfaces that are very ...

SHERIDAN, WY / ACCESS Newswire / December 12, 2025 / From 2024 to 2027, biotech R&D growth is increasingly shaped by a quiet enabler: high-purity research peptides. As labs pursue complex work in ...

Researchers have identified a possible 'Achilles' heel' in the frustration of amyloid beta peptides as they dock to the fibrils that form plaques in patients with Alzheimer's disease. Progress on ...